(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $5.29
発行日: 15 2月 2024 @ 04:56
リターン: -21.36%
前回のシグナル: 2月 14 - 05:19
前回のシグナル:
リターン: 1.15 %
Live Chart Being Loaded With Signals
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States...
Stats | |
---|---|
本日の出来高 | 79 222.00 |
平均出来高 | 180 790 |
時価総額 | 54.03M |
EPS | $0 ( 2024-04-07 ) |
次の収益日 | ( $0 ) 2024-06-27 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 4.89 |
ATR14 | $0.0100 (0.24%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-28 | Tarriff Scott | Sell | 2 119 | Common Stock |
2024-02-27 | Cahill Brian Joseph | Buy | 3 800 | Common Stock |
2024-02-27 | Cahill Brian Joseph | Sell | 1 589 | Common Stock |
2024-02-27 | Tarriff Scott | Buy | 12 950 | Common Stock |
2024-02-27 | Tarriff Scott | Sell | 3 154 | Common Stock |
INSIDER POWER |
---|
59.28 |
Last 99 transactions |
Buy: 818 589 | Sell: 362 958 |
ボリューム 相関
Eagle Pharmaceuticals Inc 相関
10 最も負の相関 | |
---|---|
AMRB | -0.956 |
NETE | -0.951 |
MORF | -0.949 |
AVDL | -0.931 |
WPRT | -0.928 |
RXDX | -0.927 |
NYMTN | -0.92 |
COKE | -0.919 |
FLMN | -0.919 |
KBWD | -0.917 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Eagle Pharmaceuticals Inc 相関 - 通貨/商品
Eagle Pharmaceuticals Inc 財務諸表
Annual | 2022 |
収益: | $316.61M |
総利益: | $221.67M (70.01 %) |
EPS: | $2.76 |
FY | 2022 |
収益: | $316.61M |
総利益: | $221.67M (70.01 %) |
EPS: | $2.76 |
FY | 2021 |
収益: | $171.55M |
総利益: | $129.37M (75.41 %) |
EPS: | $-0.0359 |
FY | 2020 |
収益: | $187.80M |
総利益: | $142.34M (75.79 %) |
EPS: | $0.890 |
Financial Reports:
No articles found.
Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。